|
New tests available now are: Complement C4 genotype Bradykinin Prostaglandin D2 11 beta Prostaglandin F2 alpha Prostaglandin DM Mast cell activation markers RNA Polymerase III antibodies Extended myositis blot (additional antibodies available: TIF1g, MDA5, NXP2 and SAE1) Thrombospondin type-1 domain-containing 7A NMDAR (N-Methyl-D-Aspartate Receptor Antibodies) HLA B27 HLA DQ2 and HLA DQ8 ALEX Allergen Chip Faecal Immunochemical Test (FIT) Autoimmune Encephalitis Screen (NMDAR, CASPR2, LGI1, AMPAR1, AMPAR2 and GABA receptor antibodies) Myelin Oligodendrocyte Glycoprotein (MOG) antibodies Skin Antibodies: BP180, BP230, Desmoglein 1 (DSG1) and Desmoglein 3 (DSG3) Urine gliadin immunogenic peptides (Awaiting UKAS ETS outcome) IgA Tissue transglutaminase 6 antibodies (Awaiting UKAS ETS outcome) Voltage Gated Potassium Channel (VGKC) antibodies (Awaiting UKAS ETS outcome) New tests undergoing development: IgG Tissue transglutaminase 6 antibodies Rituximab quantitation and antibodies MUSK antibodies Scleroderma Screen Covid 19 ELISA/Lateral flow Newborn screening for SCID (flow cytometry panel) Ganglioside antibodies (extended panel)
|